Literature DB >> 16454699

Chemokines in gastrointestinal disorders.

K Gijsbers1, K Geboes, J Van Damme.   

Abstract

The intestine is constantly challenged by food antigens and pathogens and is therefore in need of a good working innate and adaptive immune response. Chemokines are important modulators as they assure the directed movement of immune cells within the body. In addition, chemokines play an important role in hematopoiesis, angiogenesis and tumor metastasis. This review focuses on chemokines and gastrointestinal disorders, more particularly on inflammatory bowel diseases and gastrointestinal tumors. In a first part, the current knowledge on chemokine expression in inflammatory bowel diseases is summarized. Idiopathic inflammatory bowel diseases are characterized by an uncontrolled immune response. The resulting chronic inflammation of the intestine involves massive infiltration of immune cells, causing intestinal damage by the release of cytokines and proteolytic enzymes. Chemokines are believed to be key mediators in this process of aberrant leukocyte recruitment. Chemokine expression in inflammatory bowel disease strongly correlates with the grade of disease activity. The potential therapeutic use of chemokines in gastrointestinal tumors by the use of gene therapy is also reviewed. Chemokines have therapeutic potential in anti-tumor therapy by their angiostatic effect. On the other hand, chemokines can augment the cell-mediated adaptive immune response and thereby exert anti-tumor activity. However, chemokines can passively favor escape of tumor cells by stimulating the release of tissue degrading matrix metalloproteinases and can actively promote metastasis of chemokine receptor-expressing tumor cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16454699     DOI: 10.2174/138945006775270222

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  7 in total

1.  Chemokine C-C motif receptor 5 and C-C motif ligand 5 promote cancer cell migration under hypoxia.

Authors:  Sensen Lin; Shuying Wan; Li Sun; Jialiang Hu; Dongdong Fang; Renping Zhao; Shengtao Yuan; Luyong Zhang
Journal:  Cancer Sci       Date:  2012-04-12       Impact factor: 6.716

2.  N-acetyl-L-cysteine combined with mesalamine in the treatment of ulcerative colitis: randomized, placebo-controlled pilot study.

Authors:  Luis G Guijarro; Jose Mate; Javier P Gisbert; Jose Luis Perez-Calle; Ignacio Marin-Jimenez; Encarna Arriaza; Tomas Olleros; Mario Delgado; Maria S Castillejo; David Prieto-Merino; Venancio Gonzalez Lara; Amado-Salvador Pena
Journal:  World J Gastroenterol       Date:  2008-05-14       Impact factor: 5.742

3.  The atypical chemokine receptor D6 contributes to the development of experimental colitis.

Authors:  Yvonne Bordon; Chris A H Hansell; David P Sester; Mairi Clarke; Allan McI Mowat; Robert J B Nibbs
Journal:  J Immunol       Date:  2009-04-15       Impact factor: 5.422

Review 4.  The role of chemokines in intestinal inflammation and cancer.

Authors:  Dingzhi Wang; Raymond N Dubois; Ann Richmond
Journal:  Curr Opin Pharmacol       Date:  2009-09-04       Impact factor: 5.547

5.  Enhanced levels of chemokines and their receptors in the colon of microscopic colitis patients indicate mixed immune cell recruitment.

Authors:  Sezin Günaltay; Ashok Kumar Kumawat; Nils Nyhlin; Johan Bohr; Curt Tysk; Olof Hultgren; Elisabeth Hultgren Hörnquist
Journal:  Mediators Inflamm       Date:  2015-04-09       Impact factor: 4.711

6.  Mechanical stress is a pro-inflammatory stimulus in the gut: in vitro, in vivo and ex vivo evidence.

Authors:  You-Min Lin; Feng Li; Xuan-Zheng Shi
Journal:  PLoS One       Date:  2014-09-02       Impact factor: 3.240

7.  Temporal colonic gene expression profiling in the recurrent colitis model identifies early and chronic inflammatory processes.

Authors:  Bas Kremer; Rob Mariman; Marjan van Erk; Tonny Lagerweij; Lex Nagelkerken
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.